Intellia's (NTLA) CRISPR Therapies Show Promise Amid Competition

Published on December 31, 2021

While Intellia's (NTLA) pipeline is in early-stage clinical studies, its development is progressing well. Collaborations are a primary source of revenues in the absence of a marketed product.

Continue reading on website
Other news

Why is it Worth Buying Earthstone (ESTE) Stock Right Now

December 31, 2021
A notable announcement that impressed investors this year is Earthstone Energy's (ESTE) recent deal to acquire Northern Delaware Basin assets for roughly $604 million.

SNDR vs. ASR: Which Stock Should Value Investors Buy Now?

December 31, 2021
SNDR vs. ASR: Which Stock Is the Better Value Option?